Therapeutics News and Research

RSS

WHO member states adopt landmark Pandemic Agreement

Member States of the World Health Organization (WHO) today formally adopted by consensus the world's first Pandemic Agreement.

20 May 2025

This news might ruin your appetite — and summer

It's a marvel of food technology: ice cream that resists melting.

20 May 2025

NELL2 identified as a key regulator of bone formation and fat suppression

A recent study identifies Neural EGFL-like 2 (NELL2), a secreted protein, as a key regulator of bone homeostasis, offering potential therapeutic applications for osteoporosis.

19 May 2025

New machine learning model shows promise in predicting postpartum depression risk

Postpartum depression (PPD) affects up to 15 percent of individuals after childbirth. Early identification of patients at risk of PPD could improve proactive mental health support.

19 May 2025

New gene editor evoCAST enables precise insertion of complete genes

Ask scientists what gene editing tool is most needed to advance gene therapy, and they'd probably describe a system that's now close to realization in the labs of Samuel Sternberg at Columbia University Vagelos College of Physicians and Surgeons and David Liu at the Broad Institute of MIT and Harvard.

15 May 2025

Ubrogepant relieves early migraine symptoms and may help prevent full-blown attacks

A phase 3 trial found that ubrogepant, given during the premonitory phase of migraine, improved common warning symptoms such as fatigue, light and sound sensitivity, and neck pain. These benefits were observed as early as one hour post-treatment, suggesting early intervention can reduce migraine burden.

15 May 2025

Customized CRISPR gene editing therapy successfully treats infant with rare disease

In a historic medical breakthrough, a child diagnosed with a rare genetic disorder has been successfully treated with a customized CRISPR gene editing therapy by a team at Children's Hospital of Philadelphia (CHOP) and Penn Medicine.

15 May 2025

Discovery of second learning system in the brain sheds light on habit formation

Neuroscientists at the Sainsbury Wellcome Centre (SWC) at UCL have discovered that the brain uses a dual system for learning through trial and error.

14 May 2025

Multiple laboratory techniques can provide a wealth of knowledge about brain cancer

Clinicians from the Johns Hopkins Kimmel Cancer Center and four other institutions have demonstrated that doctors can gain a wealth of knowledge about a patient's cancer by using multiple laboratory techniques to study tumor tissue taken from needle biopsies of glioblastoma, a highly aggressive form of brain cancer.

14 May 2025

Urban children have more pro-allergic immune cells than rural peers

Scientists discovered that a previously uncharacterized subset of immune cells may play a critical role in the development of allergic diseases and explain differences between urban and rural populations.

14 May 2025

Research highlights extended duration of ADHD medication for Finnish children

A recent study by the University of Turku and the University of Helsinki in Finland and the Finnish Social Insurance Institution Kela reveals that the average duration of ADHD medication for children and adolescents is more than three years.

14 May 2025

Hormone FGF21 reverses fatty liver disease by signaling the brain

A pioneering research study published today in Cell Metabolism details how the hormone FGF21 (fibroblast growth factor 21) can reverse the effects of fatty liver disease in mice. The hormone works primarily by signaling the brain to improve liver function.

13 May 2025

Exploring the role of RNA binding proteins and circular RNAs in cancer

The interaction between RNA-binding proteins (RBPs) and circular RNAs (circRNAs) has emerged as a key area of interest in understanding cancer biology.

12 May 2025

Review spotlights MYC as a multidimensional therapeutic target in cancer

A new review in Genes and Diseases explores the central role of MYC, a master regulatory protein, in the development and progression of cancer, spotlighting its potential as a multidimensional therapeutic target.

12 May 2025

RANBP2 identified as key regulator in the progression of multiple solid tumors

The nuclear pore complex protein RANBP2 has emerged as a critical factor in the development and progression of various solid malignancies.

12 May 2025

Mitochondrial DNA editing offers new hope for neurodegenerative disease treatment

Mitochondrial DNA (mtDNA) editing has emerged as a revolutionary approach in the fight against neurodegenerative diseases (NDDs).

12 May 2025

HER3 reemerges as a key driver of cancer progression and therapy resistance

A new publication shines a spotlight on HER3, a long-overlooked member of the ErbB receptor family, revealing its critical role in cancer progression and resistance to therapy.

12 May 2025

Novel Alzheimer's therapy shows low risk of severe side effects

The Food and Drug Administration's approval in 2023 of lecanemab - a novel Alzheimer's therapy shown in clinical trials to modestly slow disease progression - was met with enthusiasm by many in the field as it represented the first medication of its kind able to influence the disease.

12 May 2025

PhoreMost makes key appointments to Board to advance development of next-generation degrader therapeutics

PhoreMost Ltd., a next-generation targeted protein degradation (TPD) company progressing a pipeline of degrader therapeutics within oncology and inflammation, today announced Barbara Duncan has joined its Board as Chair, and Stephen Dilly as Non-Executive Director.

From PhoreMost 12 May 2025

ELRIG announces keynote speakers for Drug Discovery 2025

ELRIG, a not-for-profit, volunteer-led organization dedicated to the global drug discovery community, has revealed the keynote speakers for its flagship event, Drug Discovery 2025. Taking place at the ACC in Liverpool, UK from 21-22 October, the conference will feature presentations from Professor Heather Pinkett (Northwestern University) and Dr Dafydd Owen (Pfizer Medicine Design).

From ELRIG (UK) Ltd. 12 May 2025